Fenfluramine (Fintepla®) for Lennox-Gastaut Syndrome . HTA ID: 23051

Assessment Status Awaiting full HTA submission from Applicant
HTA ID 23051
Drug Fenfluramine
Brand Fintepla®
Indication Fenfluramine (Fintepla®) is indicated for patients (two years of age and older) with Lennox-Gastaut Syndrome as an add-on therapy to other anti-epileptic medicines.
Assessment Process
Rapid review commissioned 09/08/2023
Rapid review completed 14/09/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of fenfluramine for this indication compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 29/09/2023
Pre-submission consultation with Applicant 07/11/2023